Can Capital Lease Obligations from 2010 to 2024
| CANF Stock | USD 2.10 0.05 2.44% |
Capital Lease Obligations | First Reported 2010-12-31 | Previous Quarter 40 K | Current Value 58.9 K | Quarterly Volatility 17.1 K |
Check Can Fite financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Can Fite's main balance sheet or income statement drivers, such as Depreciation And Amortization of 21.5 K, Interest Expense of 13.3 K or Total Revenue of 1.1 M, as well as many indicators such as Price To Sales Ratio of 12.14, Dividend Yield of 0.0 or PTB Ratio of 1.45. Can financial statements analysis is a perfect complement when working with Can Fite Valuation or Volatility modules.
Can | Capital Lease Obligations |
Latest Can Fite's Capital Lease Obligations Growth Pattern
Below is the plot of the Capital Lease Obligations of Can Fite Biopharma over the last few years. Can Fite Biopharma capital lease obligations are the amount due for long-term lease agreements that are nearly equivalent to Can Fite asset purchases. For example, Can Fite can use a capital lease to finance the purchase of an asset without ever buying it. A capital lease gives companies such as Can Fite control over an asset for a big portion of its life. It is the total obligations of a company under capital leases, which are lease agreements that transfer substantially all risks and rewards of ownership to the lessee. Can Fite's Capital Lease Obligations historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Can Fite's overall financial position and show how it may be relating to other accounts over time.
| Capital Lease Obligations | 10 Years Trend |
|
Capital Lease Obligations |
| Timeline |
Can Capital Lease Obligations Regression Statistics
| Arithmetic Mean | 73,459 | |
| Geometric Mean | 71,719 | |
| Coefficient Of Variation | 23.25 | |
| Mean Deviation | 8,794 | |
| Median | 75,000 | |
| Standard Deviation | 17,078 | |
| Sample Variance | 291.7M | |
| Range | 84K | |
| R-Value | (0.20) | |
| Mean Square Error | 301.3M | |
| R-Squared | 0.04 | |
| Significance | 0.47 | |
| Slope | (770.86) | |
| Total Sum of Squares | 4.1B |
Can Capital Lease Obligations History
About Can Fite Financial Statements
Can Fite stakeholders use historical fundamental indicators, such as Can Fite's Capital Lease Obligations, to determine how well the company is positioned to perform in the future. Although Can Fite investors may analyze each financial statement separately, they are all interrelated. For example, changes in Can Fite's assets and liabilities are reflected in the revenues and expenses on Can Fite's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Can Fite Biopharma. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Capital Lease Obligations | 40 K | 58.9 K |
Currently Active Assets on Macroaxis
When determining whether Can Fite Biopharma is a strong investment it is important to analyze Can Fite's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Can Fite's future performance. For an informed investment choice regarding Can Stock, refer to the following important reports:Check out the analysis of Can Fite Correlation against competitors. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Can Fite. If investors know Can will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Can Fite listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.60) | Quarterly Revenue Growth (0.19) | Return On Assets (0.57) | Return On Equity (1.58) |
The market value of Can Fite Biopharma is measured differently than its book value, which is the value of Can that is recorded on the company's balance sheet. Investors also form their own opinion of Can Fite's value that differs from its market value or its book value, called intrinsic value, which is Can Fite's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Can Fite's market value can be influenced by many factors that don't directly affect Can Fite's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Can Fite's value and its price as these two are different measures arrived at by different means. Investors typically determine if Can Fite is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Can Fite's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.